Compare Bristol-Myers Squibb Co (BMY) vs JPMorgan Ultra Short Income ETF (JPST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs JPMorgan Ultra Short Income ETF — how do they compare? Bristol-Myers Squibb Co trades at $56.99 (market cap $116.30B), while JPMorgan Ultra Short Income ETF trades at $50.47. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while JPMorgan Ultra Short Income ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, JPMorgan Ultra Short Income ETF nearer its low. Which is the better fit depends on your goals.
| BMY | JPST | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $62.37 | $50.78 |
52-Week Low | $42.60 | $50.40 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
JPST trades at $50.44, down 0.02% with a bearish technical signal from moving averages. The ETF focuses on high-quality, short-term bonds, offering monthly dividends and capital preservation. Recent news highlights strong institutional inflows and its role as a cash alternative in volatile markets. Technical indicators show neutral oscillators but overall bearish momentum, with support and resistance clustered around $50.
Outlook remains stable for income-focused investors seeking low duration risk, though rising Treasury yields pose a headwind. Key risks include interest rate sensitivity and credit spread changes. Institutional ownership trends indicate growing advisor interest, supporting its defensive profile in uncertain rate environments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About JPMorgan Ultra Short Income ETF
JPST is an actively managed ETF that invests in short-term, investment-grade fixed income securities. It aims to provide current income and capital preservation while maintaining high liquidity.
Read more on JPST →
